Background
==========

A number of genes are recognized as being potentially relevant to cancers. One way to evaluate such genes is to assess their relationship to prognosis. At present, many cancer microarray datasets with clinical annotation have become available in the public domain and provide vast opportunities to link gene expression to prognosis. However, the data are not easy to access and analyze without an effective analysis platform.

Standard survival analysis consists of two steps: 1) grouping patients and 2) comparing the risk difference of the groups. When conducting survival analysis based on continuous measurement such as gene expression, determination of the appropriate cutpoints for groupings remains a critical and difficult task. Thus, although two pioneer databases, ITTACA \[[@B1]\] and REMBRANDT <http://rembrandt.nci.nih.gov>, have provided survival analysis functionality with user defined cutpoints for several focused cancer microarray datasets, researchers without prior biological knowledge or assumptions for the gene may end up using an arbitrary threshold (e.g. median, tertile, quartile) that does not necessarily reflect the biology of the gene or may laboriously test a number of possible cutpoints.

The minimum *P*-value approach is a comprehensive method to find the optimal risk separation cutpoint in continuous measurements and have shown the utility in the analyses of tumor size \[[@B2]\], cell cycle phase estimation measurement \[[@B3]\], and gene copy number \[[@B4]\]. In addition, it is intuitive for oncologists, and thus, a systematic application of this approach to gene expression from microarray seems logical. Recent studies have reported expression thresholds at which the gene becomes a contributor to the development of the cancer such as Bub1 for tumorigenesis \[[@B5]\], HOXB4 for cellular transformation \[[@B6]\], and MYC for tumor maintenance \[[@B7]\], and provided a rationale for the application to gene expression. Thus, we developed \"PrognoScan\", a database featuring a large collection of publicly available cancer microarray datasets with clinical annotation and a tool for assessing the relationship between gene expression and prognosis using the minimum *P*-value approach. This database enables systematic meta-analysis of the prognostic value of a gene in multiple datasets and consequently will accelerate cancer research.

Construction and content
========================

Data collection
---------------

Cancer microarray datasets with clinical annotation were intensively collected from the public domain including Gene Expression Omnibus (GEO) \[[@B8]\], ArrayExpress \[[@B9]\] and individual laboratory web sites, under the following criteria: 1) includes patient information on survival event and time, 2) contains large enough sample sizes to enable survival analysis, 3) is derived from a \'whole genome\' platform and has no values missing so quantile normalization will function properly and 4) is derived from a platform for which probe annotation for a public identifier (e.g. gene symbol, GenBank accession number, UniGene ID) is available. As of February 2009, the collection included more than 40 datasets of various cancer types spanning a wide range of cancers including bladder, blood, breast, brain, esophagus, head and neck, kidney, lung, and ovarian (Table [1](#T1){ref-type="table"}) \[[@B10]-[@B35]\], far more comprehensive than both ITTACA, which focuses on bladder cancer, breast cancer and uveal melanoma, and REMBRANDT, which specializes in brain cancers. Because some samples were used more than once by more than one study, the origin of the samples was checked. Sample duplications within a dataset were dealt with by leaving one representative arbitrary. Sample overlaps among datasets were accepted, because the study design designated by each contributor may be of value. The collected microarray datasets were standardized by using quantile normalization. Probe annotations were retrieved from GEO and ArrayExpress. Each probe was mapped to an Entrez Gene ID by querying the accompanied public identifier in UniGene database. The information in the dataset was manually curated and includes 1) study design-cohort, cancer type, subtype, endpoint, therapy history and pathological parameters-and 2) experimental procedure-sample preparation, storage, array type and signal processing method. To assess prognostic value of genes in various contexts, available endpoints such as overall survival (OS), recurrence free survival (RFS), event free survival (EFS), and distant-metastasis free survival (DMFS) were adopted as much as possible. All tables were relationally linked and stored in the MySQL server.

###### 

Dataset content from PrognoScan

  **Dataset**       **Cancer type**        **Subtype**                   **Cohort**                                                **Author/Contributor**         **Array type**          **n**     **Data source**
  ----------------- ---------------------- ----------------------------- --------------------------------------------------------- ------------------------------ ----------------------- --------- --------------------
  GSE13507          Bladder cancer         Transitional cell carcinoma   Cheongju                                                  Kim                            Human-6 v2              n = 165   GEO
  GSE5287           Bladder cancer                                       Aarhus (1995--2004)                                       Als *et al*. \[[@B10]\]        HG-U133A                n = 30    GEO
  GSE12417-GPL570   Blood cancer           AML                           AMLCG (2004)                                              Metzeler *et al*. \[[@B11]\]   HG-U133_Plus_2          n = 79    GEO
  GSE12417-GPL96    Blood cancer           AML                           AMLCG (1999--2003)                                        Metzeler *et al*. \[[@B11]\]   HG-U133A                n = 163   GEO
  GSE12417-GPL97    Blood cancer           AML                           AMLCG (1999--2003)                                        Metzeler *et al*. \[[@B11]\]   HG-U133B                n = 163   GEO
  GSE8970           Blood cancer           AML                           San Diego                                                 Raponi *et al*. \[[@B12]\]     HG-U133A                n = 34    GEO
  GSE4475           Blood cancer           B-cell lymphoma               Berlin (2003--2005)                                       Hummel *et al*. \[[@B13]\]     HG-U133A                n = 158   GEO
  E-TABM-346        Blood cancer           DLBCL                         GELA (1998--2000)                                         Jais *et al*. \[[@B14]\]       HG-U133A                n = 53    ArrayExpress
  GSE2658           Blood cancer           Multiple myeloma              Arkansas                                                  Zhan *et al*. \[[@B15]\]       HG-U133_Plus_2          n = 559   GEO
  E-TABM-158        Breast cancer                                        UCSF, CPMC (1989--1997)                                   Chin *et al*. \[[@B16]\]       HG-U133A                n = 129   ArrayExpress
  GSE11121          Breast cancer                                        Mainz (1988--1998)                                        Schmidt *et al*. \[[@B17]\]    HG-U133A                n = 200   GEO
  GSE1378           Breast cancer                                        MGH (1987--2000)                                          Ma *et al*. \[[@B18]\]         Arcturus 22 k           n = 60    GEO
  GSE1379           Breast cancer                                        MGH (1987--2000)                                          Ma *et al*. \[[@B18]\]         Arcturus 22 k           n = 60    GEO
  GSE1456-GPL96     Breast cancer                                        Stockholm (1994--1996)                                    Pawitan *et al*. \[[@B19]\]    HG-U133A                n = 159   GEO
  GSE1456-GPL97     Breast cancer                                        Stockholm (1994--1996)                                    Pawitan *et al*. \[[@B19]\]    HG-U133B                n = 159   GEO
  GSE2034           Breast cancer                                        Rotterdam (1980--1995)                                    Wang *et al*. \[[@B20]\]       HG-U133A                n = 286   GEO
  GSE2990           Breast cancer                                        Uppsala, Oxford                                           Sotiriou *et al*. \[[@B21]\]   HG-U133A                n = 187   GEO
  GSE3143           Breast cancer                                        Duke                                                      Bild *et al*. \[[@B22]\]       HG-U95A                 n = 158   GEO
  GSE3494-GPL96     Breast cancer                                        Uppsala (1987--1989)                                      Miller *et al*. \[[@B23]\]     HG-U133A                n = 236   GEO
  GSE3494-GPL97     Breast cancer                                        Uppsala (1987--1989)                                      Miller *et al*. \[[@B23]\]     HG-U133B                n = 236   GEO
  GSE4922-GPL96     Breast cancer                                        Uppsala (1987--1989)                                      Ivshina *et al*. \[[@B24]\]    HG-U133A                n = 249   GEO
  GSE4922-GPL97     Breast cancer                                        Uppsala (1987--1989)                                      Ivshina *et al*. \[[@B24]\]    HG-U133B                n = 249   GEO
  GSE6532-GPL570    Breast cancer                                        GUYT                                                      Loi *et al*. \[[@B25]\]        HG-U133_Plus_2          n = 87    GEO
  GSE7378           Breast cancer                                        UCSF                                                      Zhou *et al*. \[[@B26]\]       U133AAofAv2             n = 54    GEO
  GSE7390           Breast cancer                                        Uppsala, Oxford, Stockholm, IGR, GUYT, CRH (1980--1998)   Desmedt *et al*. \[[@B27]\]    HG-U133A                n = 198   GEO
  GSE7849           Breast cancer                                        Duke (1990--2001)                                         Anders *et al*. \[[@B28]\]     HG-U95A                 n = 76    GEO
  GSE9195           Breast cancer                                        GUYT2                                                     Loi *et al*. \[[@B25]\]        HG-U133_Plus_2          n = 77    GEO
  GSE9893           Breast cancer                                        Montpellier, Bordeaux, Turin (1989--2001)                 Chanrion *et al*. \[[@B29]\]   MLRG Human 21 K V12.0   n = 155   GEO
  GSE11595          Esophagus cancer       Adenocarcinoma                Sutton                                                    Giddings                       CRUKDMF_22 K_v1.0.0     n = 34    GEO
  GSE7696           Glioma                 Glioblastoma                  Lausanne                                                  Murat *et al*. \[[@B30]\]      HG-U133_Plus_2          n = 70    GEO
  GSE4271-GPL96     Glioma                                               MDA                                                       Phillips *et al*. \[[@B31]\]   HG-U133A                n = 77    GEO
  GSE4271-GPL97     Glioma                                               MDA                                                       Phillips *et al*. \[[@B31]\]   HG-U133B                n = 77    GEO
  GSE2837           Head and neck cancer   Squamous cell carcinoma       VUMC, VAMC, UTMDACC (1992--2005)                          Chung *et al*. \[[@B32]\]      U133_X3P                n = 28    GEO
  HARVARD-LC        Lung cancer            Adenocarcinoma                Harvard                                                   Beer *et al*. \[[@B33]\]       HG-U95A                 n = 84    Author\'s web site
  MICHIGAN-LC       Lung cancer            Adenocarcinoma                Michigan (1994--2000)                                     Beer *et al*. \[[@B33]\]       HuGeneFL                n = 86    Author\'s web site
  GSE11117          Lung cancer            NSCLC                         Basel                                                     Baty                           Novachip human 34.5 k   n = 41    GEO
  GSE3141           Lung cancer            NSCLC                         Duke                                                      Bild *et al*. \[[@B22]\]       HG-U133_Plus_2          n = 111   GEO
  GSE4716-GPL3694   Lung cancer            NSCLC                         Nagoya (1995--1996)                                       Tomida *et al*. \[[@B34]\]     GF200                   n = 50    GEO
  GSE4716-GPL3696   Lung cancer            NSCLC                         Nagoya (1995--1996)                                       Tomida *et al*. \[[@B34]\]     GF201                   n = 50    GEO
  GSE8894           Lung cancer            NSCLC                         Seoul                                                     Son                            HG-U133_Plus_2          n = 138   GEO
  GSE4573           Lung cancer            Squamous cell carcinoma       Michigan (1991--2002)                                     Raponi *et al*. \[[@B35]\]     HG-U133A                n = 129   GEO
  DUKE-OC           Ovarian cancer                                       Duke                                                      Bild *et al*. \[[@B22]\]       HG-U133A                n = 134   Author\'s web site
  GSE8841           Ovarian cancer                                       Milan                                                     Mariani                        G4100A                  n = 83    GEO
  E-DKFZ-1          Renal cell carcinoma                                 RZPD                                                      Sueltmann                      A-RZPD-20               n = 74    ArrayExpress

Abbreviations: AML, Acute myelocytic leukemia; DLBCL, Diffuse large B-cell lymphoma; NSCLC, Non-small cell lung cancer

Data analysis
-------------

Survival analysis in PrognoScan employs the minimum *P*-value approach \[[@B2]\] to find the cutpoint in continuous gene expression measurement for grouping patients. First, patients are ordered by expression value of a given gene. Next, patients are divided into two (high and low) expression groups at all potential cutpoint, and the risk differences of the two groups are estimated by log-rank test. Then, optimal cutpoint that gives the most pronounced *P*-value (*P*~min~) is selected.

This exploratory approach, however, is known to cause inflation of a type I error because it conducts multiple correlated testing \[[@B36]-[@B38]\]. Thus, *P*-value correction is conducted to control the error rate using the following formula \[[@B39]\].

where *z*is the (1 - *P*~min~/2)-quantile of the standard normal distribution, *φ*denotes the standard normal density function, and \[*ε*, 1 - *ε*\] denote the range of the quantile considered to be cutpoints. PrognoScan uses *ε*= 0.1 to avoid small groupings from cutpoints of \< 0.1 or \> 0.9 quantile. For any given gene, this cutpoint determination and prognostic value assessment can be applied to all possible combinations of dataset, endpoint and probe. For convenience, we term each combination as \"test\". Note that, because probe design for each gene differs, the number of possible tests varies according to the gene. For statistical analysis and visualization, R packages <http://www.r-project.org> are used.

Utility
=======

The top page of PrognoScan is quite simple and the user need only input gene identifier(s) (Fig. [1A](#F1){ref-type="fig"}). To show the features of the database and its utility, we give three meta-analysis examples. The first example is MKI67, a well known tumor proliferation marker. The prognostic value of MKI67 protein expression has been reported for many types of malignant tumor including brain, breast, and lung cancer and a few exceptions for certain tumors such as non-Hodgkin\'s lymphoma \[[@B40]\]. When given the gene, PrognoScan displays a summary in table format of tests for the gene with columns for dataset, cancer type, subtype, endpoint, cohort, contributor, array type, probe ID, number of patient, optimal cutpoint, *P*~min~and *P*~cor~as Fig. [1B](#F1){ref-type="fig"} for MKI67 (shown in full in Additional file [1](#S1){ref-type="supplementary-material"}). In the table, 52 out of 152 tests showed an association between microarray expression and cancer prognosis (bladder 3/5, blood 6/28, breast 39/83, brain 3/8, esophagus 0/1, head and neck 0/4, kidney 0/1, lung 1/16, ovarian 0/6) with 5% significance level. Clicking the probe ID in the list reveals a detailed report, which includes further annotations for the dataset (Fig. [2A](#F2){ref-type="fig"}) and four intuitive visualization panels (Fig. [2B--E](#F2){ref-type="fig"}). The example of the Rotterdam cohort for DMFS depicts that patients can be dichotomized at the 34 percentile to give the minimum *P*-value and the group with high MKI67 expression has poorer survival (*P*~cor~= 0.0078). We found all tests but one for B-cell lymphoma OS showed a positive correlation to poorer survival, consistent with previous study results \[[@B40]\]. We further confirmed that the expressions of other well known proliferation markers TOP2A, PCNA and Aurora A also showed association with poorer survival in various tests (Additional file [2](#S2){ref-type="supplementary-material"}).

![**PrognoScan screenshot and sample search results (part 1)**. (A) The top page is quite simple and only requires entering the gene identifier(s). (B) Summary table for MKI67, shown here in part (See Additional file [1](#S1){ref-type="supplementary-material"} for the full table.). Column headings include dataset, cancer type, subtype, endpoint, cohort, contributor, array type, probe ID, number of patients, optimal cutpoint, *P*~min~and *P*~cor~. A statistically significant value of *P*~cor~is given in red font. Each dataset has a link to the public domain where the raw data is archived. By clicking a probe ID in the summary table, a detailed report for the test is displayed. The table can be downloaded in a tab delimited file from the button at bottom.](1755-8794-2-18-1){#F1}

![**PrognoScan screenshot and sample search results (part 2)**. (A) Annotation table. Row headings are color-coded. For example, headings of details such as therapy history, sample type and pathological parameters are highlighted in yellow and basic attributes in blue. (B) Expression plot. Patients are ordered by the expression values of the given gene. The X-axis represents the accumulative number of patients and the Y-axis represents the expression value. Straight lines (cyan) show the optimal cutpoints that dichotomize patients into high (red) and low (blue) expression groups. (C) Expression histogram. The distribution of the expression value is presented where the X-axis represents the number of patients and the Y-axis represents the expression value on the same scale as the expression plot. The line of the optimal cutpoint is also shown (cyan). (D) *P*-value plot. For each potential cutpoint of expression measurement, patients are dichotomized and survival difference between high and low expression groups is calculated by log-rank test. The X-axis represents the accumulative number of patients on the same scale as the expression plot and the Y-axis represents raw *P*-values on a log scale. The cutpoint to minimize the *P*-value is determined and indicated by the cyan line. The gray line indicates the 5% significance level. (E) Kaplan-Meier plot. Survival curves for high (red) and low (blue) expression groups dichotomized at the optimal cutpoint are plotted. The X-axis represents time and the Y-axis represents survival rate. 95% confidence intervals for each group are also indicated by dotted lines.](1755-8794-2-18-2){#F2}

The second example is SIX1, emerging as a tumor-susceptible gene. This homeobox gene has been shown to promote tumor progression through direct activation of Cyclin A1 \[[@B41],[@B42]\] and to associate with prognosis of late-stage ovarian cancer \[[@B43]\] and hepatocellular carcinoma \[[@B44]\]. It has also been reported that SIX1 can be amplified and/or overexpressed in breast cancers \[[@B45],[@B46]\]. Nonetheless, to our knowledge, association with breast cancer prognosis has not yet been demonstrated. And so we tested SIX1. For ovarian cancer, a clear association was not observed in three tests available in PrognoScan. For this cancer type, further subgrouping based on stage may be needed, as reported \[[@B43]\]. On the other hand, SIX1 expression was positively associated with 5 out of 28 breast cancer tests (Fig. [3](#F3){ref-type="fig"}; Uppsala cohort; *P*~cor~= 0.0002, 0.0006 and 0.0449, Uppsala+Oxford cohort; *P*~cor~= 0.0346, Stockholm cohort; *P*~cor~= 0.0354) with statistical significance, indicative of its contribution to breast cancer malignancy. In addition, SIX1 expression showed nonsignificant trend toward worse prognosis in the GUYT2 and MGH cohorts (*P*~cor~= 0.0601, 0.0729, respectively). Using PrognoScan, SIX1 expression was correlated to breast cancer prognosis in multiple tests for the first time.

![**Kaplan-Meier plots for high and low SIX1-expressing groups in breast cancers**.](1755-8794-2-18-3){#F3}

The third example is MCTS1, a candidate oncogene amplified in T cell lymphoma. MCTS1 in a xenograft model causes transformation of NIH 3T3 mouse fibroblasts \[[@B47]\] and increases tumorgenicity by promoting angiogenesis and inhibiting apoptosis \[[@B48]\]. Similar to SIX1, prognostic analysis of this gene has not been reported for any cancers. PrognoScan depicted statistical significance in several tests: blood 2/7, breast 4/21, brain 1/2, lung 2/5 (Fig. [4](#F4){ref-type="fig"}). In all these 9 tests, a higher expression of MCTS1 associated with poorer survival, suggesting proactive involvement of this gene in the malignancy in the cancers. Again, this prognostic analysis was the first to show these relationships.

![**Kaplan-Meier plots for high and low MCTS1-expressing groups in breast, lung, blood and brain cancers**.](1755-8794-2-18-4){#F4}

Discussion and conclusion
=========================

PrognoScan is a database that focuses on the prognostic value of individual genes and differs conceptually from gene signatures. van\'t Veer *et al*. showed that the \'70 gene signature\' can predict risk of breast cancer recurrence, and that pattern analysis of multifactorial gene signature has greater potential for improving cancer subtype classification and risk prediction \[[@B49]\]. On the other hand, the prognostic value of an individual gene, for which pattern analysis is not applicable, suggests underlying relevance of the gene to cancer etiology and in turn stimulates research. With the number of public cancer microarray datasets with clinical annotation currently available, it is reasonable to utilize those assets to link gene expression to prognosis. Actually, Mehra *et al*., Paulson *et al*., and Kim *et al*. interrogated published cancer microarray datasets to evaluate targeted genes, GATA3, HBP1 and CUL7, respectively \[[@B50]-[@B52]\]. In this study, candidate oncogene SIX1 was correlated to breast cancer prognosis and MCTS1 to brain, blood, breast and lung cancer prognosis for the first time. PrognoScan aims to fulfill such substantial practical requirements.

Regarding survival analysis using publicly available microarray datasets, several considerations exist:

1\) Cohorts. Datasets come from a number of different institutions around the world, and patient backgrounds differ. In addition, several datasets are based on specific subpopulations, for example, dataset GSE2034 is from lymph node-negative breast cancers, and GSE5287 is from cisplatin-containing chemotherapy-treated bladder cancers. Hence, it is possible that the specific association between gene expression and prognosis is found in a certain cohort. To give an example, Dai *et al*. reported that cell cycle genes are highly prognostic in groups with high ER expression for their age but less or nonprognostic in other groups \[[@B53]\].

2\) Quality of care. It has been reported that the hospital itself could be a factor in clinical outcome \[[@B54]-[@B56]\]. This means, even if cohorts were equivalent at the time of profiling, subsequent care may affect the clinical course of a patient.

3\) Experimental factors. Expression measurement of microarray is subject to various factors at the experiment level. Microdissection (e.g. GSE1378) would reduce contamination of mRNAs from non-cancer cells \[[@B57]\]. Formalin fixation of a sample (e.g. GSE2873) influences the quality of mRNAs \[[@B58]\]. Array type (e.g. Affymetrix, cDNA microarrays) and data processing method (e.g. MAS, RMA) can also influence gene expression measurements \[[@B59]\]. In addition, it is known that a substantial number of incorrect probes are used in microarrays \[[@B60]\].

4\) Random error. Even though there may be no relation between a gene expression and prognosis, false positives may be detected by chance.

Thus, one needs to regard the results from PrognoScan in the context of complex conditions. Currently, PrognoScan provides curated information such as cohort, therapy history, pathological parameters and array type to aid in the interpretation of the results. As a next step, developing an \"interpreter\" for complex meta-analysis result is tempting and we are now contemplating the challenge. In the meantime, we will continue collecting published datasets and will update PrognoScan every 6 months. Increased data content will help the judgment of the robustness of the prognostic value of a gene.

Further plans for PrognoScan also include development of the algorithm for finding multiple cutpoints. From the limited computational resources, cutpoint selection is currently done for two-way (high and low) expression grouping. For clinical practice, three-way (high, intermediate, and low) expression grouping can also be used. Thus, we are trying to develop a grid search algorithm, demonstrated as the \"X-Tile\" tool \[[@B61]\]. In summary, this new database provides a powerful platform for evaluating potential tumor markers and therapeutic targets, and as a result, will accelerate cancer research.

Availability and requirements
=============================

PrognoScan requires nothing other than a web browser and is available from the server at Kyushu Institute of Technology (KIT): <http://gibk21.bse.kyutech.ac.jp/PrognoScan/index.html>.
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###### Additional file 1

**Full summary table for MKI67**. A well known tumor proliferation marker MKI67 was assessed with PrognoScan and the summary table was indicated.
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###### Additional file 2

**Number of statistically significant tests for four proliferation markers among nine cancer types**. Tumor proliferation markers, TOP2A, PCNA and Aurora A were assessed with PrognoScan. Together with the result for MKI67, associations with nine cancer types were indicated.
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